Investor Presentaiton
Eurofins is present in several high growth Life Sciences
markets critical to fight the COVID-19 pandemic
* eurofins
Eurofins'
position
Business line description
Oligonucleotides Production and
Next Generation Sequencing (NGS)
In Vitro Diagnostic (IVD) products
#3 worldwide 1
#1 in Europe¹
Start 2000
Start-up
Start 2016
Eurofins Genomics' expertise in the synthesis of
oligonucleotides has made the company a European
market leader and a strong global player with several
fully automated production facilities around the world.
Eurofins Genomics is also an international leader in
Sanger and NGS sequencing services and a growing
gene synthesis provider. Eurofins Genomics produces
probes, primers and positive controls, key components
for RT-PCR testing of SARS-CoV-2, from 6 production
sites in U.S., Europe, India and Japan.
Whole genome NGS sequencing of the coronavirus
supports traceability of the source of outbreaks.
Eurofins Technologies' subsidiaries Gold Standard
Diagnostics (GSD), NovaTec Immundiagnostica,
VIROTECH Diagnostics, Genescan Technologies,
Immunolab, Abraxis and Ingenasa offer an innovative
suite of IVD instruments, testing kits and testing
reagents for laboratories to carry out a large range of
clinical diagnostics for infectious diseases (Borrelia, Zika,
Chlamydia, CMV, Dengue, etc.).
GSD sells IVD instruments and testing reagents to other
Eurofins' laboratories and to 3rd party laboratories.
Eurofins Technologies has developed a complete range
of 1,500 products for industrial and clinical applications
including COVID-19 full testing portfolio (RT-PCR,
serology/antibodies, antigen rapid tests, Lateral Flow
home test/Device (LFD)), from 10 production sites.
Listed or
larger
peers
ThermoFisher, GenScript, Swift Biosciences, Merck,
Danaher, etc.
Roche, Abbott, Becton Dickinson, Hologic, Beckman
Coulter, DiaSorin, Biomerieux, Thermo Fisher, Tecan,
Idexx, etc.
1 To the best of Eurofins' knowledge, based on data available to the Group
15View entire presentation